A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
Solstice Oncology acquires porustobart from Harbour Biomed.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
2026’s first big oncology buyout is here.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
Darovasertib data are promised for the last week of March.
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
